EA033077B1 - Фармацевтическая композиция, содержащая 13 глицеридов, и ее препараты и их применение - Google Patents

Фармацевтическая композиция, содержащая 13 глицеридов, и ее препараты и их применение

Info

Publication number
EA033077B1
EA033077B1 EA201790117A EA201790117A EA033077B1 EA 033077 B1 EA033077 B1 EA 033077B1 EA 201790117 A EA201790117 A EA 201790117A EA 201790117 A EA201790117 A EA 201790117A EA 033077 B1 EA033077 B1 EA 033077B1
Authority
EA
Eurasian Patent Office
Prior art keywords
linolein
composition containing
pharmaceutical composition
preparations
diolein
Prior art date
Application number
EA201790117A
Other languages
English (en)
Other versions
EA201790117A1 (ru
Inventor
Дапэн Ли
Original Assignee
Чжэцзян Канлайтэ Груп Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201410342799.2A external-priority patent/CN105267197B/zh
Application filed by Чжэцзян Канлайтэ Груп Ко., Лтд. filed Critical Чжэцзян Канлайтэ Груп Ко., Лтд.
Publication of EA201790117A1 publication Critical patent/EA201790117A1/ru
Publication of EA033077B1 publication Critical patent/EA033077B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к фармацевтической композиции, содержащей 13 соединений: 1,3-диолеин, 1-линолеин-3-олеин, 1,2-диолеин, 1-олеин-2-линолеин, 1,2-дилинолеин, трилинолеин, 1-олеин-2,3-дилинолеин, 1-пальмитин-2,3-дилилолеин, 1,3-диолеин-2-линолеин, 1-пальмитин-2-линолеин-3-олеин, 1,3-дипальмитин-2-линолеин, триолеин и 1-пальмитин-2,3-диолеин. Изобретение также относится к фармацевтическим препаратам на основе этой композиции, способу их получения и их применению в лечении опухолей и в усилении иммунитета.
EA201790117A 2014-07-18 2015-07-17 Фармацевтическая композиция, содержащая 13 глицеридов, и ее препараты и их применение EA033077B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410342799.2A CN105267197B (zh) 2014-07-18 含有13种甘油酯的药物组合物、制剂及其应用
PCT/CN2015/084295 WO2016008441A1 (zh) 2014-07-18 2015-07-17 含有13种甘油酯的药物组合物、制剂及其应用

Publications (2)

Publication Number Publication Date
EA201790117A1 EA201790117A1 (ru) 2017-07-31
EA033077B1 true EA033077B1 (ru) 2019-08-30

Family

ID=55073638

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790117A EA033077B1 (ru) 2014-07-18 2015-07-17 Фармацевтическая композиция, содержащая 13 глицеридов, и ее препараты и их применение

Country Status (13)

Country Link
US (1) US9585858B2 (ru)
EP (1) EP3153163B1 (ru)
JP (1) JP6473801B2 (ru)
KR (1) KR20170031146A (ru)
AP (1) AP2017009706A0 (ru)
AU (1) AU2015291530B2 (ru)
CA (1) CA2954792C (ru)
DK (1) DK3153163T3 (ru)
EA (1) EA033077B1 (ru)
NZ (1) NZ726582A (ru)
PL (1) PL3153163T3 (ru)
SG (1) SG11201700122TA (ru)
WO (1) WO2016008441A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6113133B2 (ja) 2014-11-06 2017-04-12 日本メナード化粧品株式会社 幹細胞の未分化状態維持剤及び増殖促進剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1080176A (zh) * 1993-01-01 1994-01-05 浙江省中医院 薏苡仁中性油脂乳剂
CN101940738A (zh) * 2010-07-27 2011-01-12 辽宁中医药大学 薏苡仁抗癌中药及其制备方法
CN104173824A (zh) * 2014-07-18 2014-12-03 浙江康莱特集团有限公司 含有8种甘油三酯的薏苡仁油、制剂及其应用
US20140370129A1 (en) * 2013-06-14 2014-12-18 Zhejiang Kanglaite Group Co., Ltd. Dosing regimen and method for treating cancer using a coix seed oil emulsion

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30249A (en) * 1992-09-16 1997-02-05 Zhejiang Provincial Hospital O Neutral lipids from endosperm of job's tears
CN1029662C (zh) * 1992-09-17 1995-09-06 李大鹏 薏苡仁中性油脂及其提取方法
JP2002212586A (ja) * 2001-01-19 2002-07-31 Kanegafuchi Chem Ind Co Ltd 油脂の精製方法
CN1200995C (zh) * 2002-09-28 2005-05-11 李大鹏 超临界二氧化碳提取薏苡仁粗油方法
CN1234828C (zh) * 2002-11-21 2006-01-04 上海高科联合生物技术研发有限公司 超临界二氧化碳萃取薏苡仁油的方法
CN1778380A (zh) * 2004-11-23 2006-05-31 乔志亚生技股份有限公司 薏仁油萃取的方法及组成分及其疗效
CN101036761B (zh) * 2007-04-23 2010-05-19 肖志勇 一种薏苡仁油的制备方法
CN102177978B (zh) * 2011-04-14 2013-01-30 西南大学 薏苡仁米糠及其运用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1080176A (zh) * 1993-01-01 1994-01-05 浙江省中医院 薏苡仁中性油脂乳剂
CN101940738A (zh) * 2010-07-27 2011-01-12 辽宁中医药大学 薏苡仁抗癌中药及其制备方法
US20140370129A1 (en) * 2013-06-14 2014-12-18 Zhejiang Kanglaite Group Co., Ltd. Dosing regimen and method for treating cancer using a coix seed oil emulsion
CN104173824A (zh) * 2014-07-18 2014-12-03 浙江康莱特集团有限公司 含有8种甘油三酯的薏苡仁油、制剂及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NIU, Guilian, Investigation about the effect of LAK cells on the antitumor activity, Foreign medical sciences (Cancer Section), vol. 2, no 21, 30 April 1994 (30.04.1994), p. 65, column 1, paragraph 1 *
XIANG, Zhiming et al., Identification of triacylglycerols in coix oil by high performance liquid chromatography-atmospheric pressure chemical lonization-mass spectrometry, China Journal of Chinese Matena Medica, vol. 30, no 18, 30 September 2005 (30.09.2005), page 1436, column 2, paragraphs 2-8, p. 1437, fig. 1 *

Also Published As

Publication number Publication date
EP3153163A4 (en) 2017-05-17
CN105267197A (zh) 2016-01-27
CA2954792C (en) 2019-10-29
AU2015291530B2 (en) 2018-03-15
US20160015672A1 (en) 2016-01-21
EP3153163B1 (en) 2019-05-22
AP2017009706A0 (en) 2017-01-31
EP3153163A1 (en) 2017-04-12
SG11201700122TA (en) 2017-03-30
NZ726582A (en) 2018-06-29
JP6473801B2 (ja) 2019-02-20
PL3153163T3 (pl) 2019-11-29
AU2015291530A1 (en) 2016-12-08
WO2016008441A1 (zh) 2016-01-21
US9585858B2 (en) 2017-03-07
CA2954792A1 (en) 2016-01-21
JP2017524697A (ja) 2017-08-31
EA201790117A1 (ru) 2017-07-31
DK3153163T3 (da) 2019-08-12
KR20170031146A (ko) 2017-03-20

Similar Documents

Publication Publication Date Title
PH12017500802B1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2019015744A (es) Composiciones farmaceuticas.
SG10201810879VA (en) Pharmaceutical compounds
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
WO2016077656A3 (en) Methods and compositions for inhibition of bromodomain and extraterminal proteins
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX2018013742A (es) Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
PH12017500348A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
SG11201605868XA (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
MX2017016231A (es) Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2017009608A (es) Compuestos anticancerigenos.
WO2016069542A3 (en) Lactone compounds and methods of making and using same
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
EA033077B1 (ru) Фармацевтическая композиция, содержащая 13 глицеридов, и ее препараты и их применение
IN2014MU00495A (ru)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG TJ TM